Patients who receive chemotherapy for colorectal cancer with the prophylactic dexamethasone (DEX) for antiemesis may experience an abnormal elevation in their casual blood glucose levels. The purpose of this study was to determine the frequency of such a DEX-induced elevation in patients with metastatic colorectal cancer, and to emphasize the importance of pharmaceutical care in improving the quality of life of patients. Methods: We retrospectively analyzed data from 50 patients who had received chemotherapy with or without DEX. Results: Of the 30 patients who received DEX, 8 exhibited abnormally high blood glucose levels (>200 mg/dl on more than 2 occasions); 3 of these patients also had diabetes mellitus. None of the 20 patients who did not receive DEX exhibited a remarkable elevation in the blood glucose levels. Conclusions: We confirm that patients receiving concomitant administration of DEX with chemotherapy may exhibit elevated blood glucose levels. Because an increase in the blood glucose levels may produce symptoms indicative of diabetes such as fatigue, appropriate pharmaceutical care for early detection of the abnormal elevation in the blood glucose levels may be important in preventing complications in such patients. Palliat Care Res 2012; 7(1): 101-111
Introduction
Nausea and vomiting are the most common adverse effects of cancer chemotherapy. Recently, more effective antiemetic regimens have been developed, and the methods to prevent and control nausea and vomiting have also improved. These measures have resulted in a better quality of life (QOL) for patients undergoing chemotherapy 1) . These adverse effects of cancer chemotherapy are classified into 3 phases according to the timing of their occurrence: an anticipatory phase, an acute phase, and a delayed phase 2) . Nausea and vomiting should be assessed separately since they are essentially different events and may be caused by different mechanisms. Oncology guidelines such as those established by the National Comprehensive
Cancer Network (NCCN) 3) classify chemotherapeutic agents on the basis of their emetic potential and recommend the appropriate antiemetic drugs such as 5-HT 3 and neurokinin 1 (NK1) receptor
antagonists, depending on their emetic potential.
Dexamethasone (DEX), a corticosteroid, is used in combination with other antiemetic drugs to prevent nausea and vomiting in the acute and delayed phases 4) . Although a single DEX dose rarely causes side effects, multiple doses often result in elevated blood glucose levels, epigastric burning, and sleep disturbances 1) . We previously reported an increase in the blood glucose levels even in non-diabetic patients with high emetic risk receiving preventive DEX treatment during chemotherapy for colorectal, stomach, and breast cancer 5) . In order to ensure better QOL for cancer patients, appropriate management of elevated blood glucose level is also important, because it may result in fatigue and other conditions.
Recently, the overall survival rate of patients with metastatic colorectal cancer has increased with improved chemotherapy regimens. However, the duration of these chemotherapy regimens has also increased, and therefore, the patients may be exposed to DEX for longer periods. Consequently, the risk of DEX-induced elevation of the blood glucose levels is also likely to increase. In such cases, comprehensive care of patients by maintaining the anticancer efficacy of drugs as well as by controlling all possible side effects is necessary; this comprehensive care requires frequent and careful consultation with patients by interprofessional teams such as pharmacists 6, 7) .
In this study, we focused on chemotherapy for colorectal cancer, and retrospectively examined the frequency of elevated casual blood glucose levels as a side effect of DEX treatment during chemotherapy. In addition, the details of the pharmaceutical care provided to these patients were discussed to address the importance of monitoring the blood glucose levels in cancer chemotherapy.
Methods 1 Patients
First, we examined the frequency of elevation in the blood glucose levels in colorectal cancer patients. Clinical data were collected from the electronic charts of the patients who had undergone 
Chemotherapy regimens
The patients were administered one or more of the following chemotherapy regimens with proven efficacy in the treatment of ad- 9, 10) , and FOLFIRI (CPT-11, 5-FU + LV) regimens 11, 12) . In case of disease progression, bevacizumab (BV) was co-administered.
The patients were divided into 2 groups: the DEX-treated group Since patients received DEX treatment for preventing nausea and vomiting, the relationship between the blood glucose levels and the grading scores of the side effects was also examined.
Results
A total of 50 patients met the study criteria; of these, 30 patients received the DEX treatment. Table 1 none of the patients in the DEX− group exhibited such a change. Fig. 1 shows the time course profiles of blood glucose levels for the patients in the DEX+ group. The elevation in the blood glucose levels occurred 3-7 months after the initiation of chemotherapy, and this period varied widely among patients. As shown in Table 1 , the performance status (PS) of these 8 patients was 0. The clinical stage of cancer was determined to be IV for 6 of these patients, and
IIIA and IIIB for each of the other 2 patients. The chemotherapy consisted of the FOLFOX4 regimen for 3 patients; mFOLFOX6, for 1 patient; and IFL, for 4 patients. The duration of the chemotherapy was 8-26 months.
Regarding chemotherapy-related nausea and vomiting, the NCI-CTCAE grade in the DEX+ group was reported to be 0 (89.8%) or 1 (8.5%), and only 3 patients exhibited grade 2 or 3 during the chemotherapy period, suggesting that nausea and vomiting in these patients were almost completely prevented by DEX administration.
The relationship between the blood glucose levels and the NCI- CTCAE grade, which were measured on the same days, is shown in Fig. 2 for all 30 patients. In patients with blood glucose levels greater than 200 mg/dL, the grade was almost 0, and nausea and vomiting were well controlled.
The details of the 8 patients who exhibited an unexpected elevation in the blood glucose levels are summarized in Table 2 and Fig. 3 . The timing of the elevation and the cumulative DEX doses varied between the patients, and no clear correlation was observed between the elevated glucose levels and DEX dosage.
We carefully monitored the patients exhibiting an abnormal elevation of the blood glucose levels for side effects by examining the vital signs and by frequent communication with the patients.
The details of the pharmaceutical care provided to these patients are as follows: patients #1, #2, #3, and #5 reported cancer pain Fig. 2 Correlation between casual blood glucose levels and grading scores for nausea and vomiting Circle: Data for patients with elevated blood glucose levels (BS＋). Triangle: Data for patients without elevated blood glucose levels (BS−). All available data points from individual patients are plotted. Blood glucose levels and grading scores for nausea and vomiting were measured on the same days. 
Discussion
In our original institutional guidelines for cancer chemotherapy, blood glucose levels was included to be measured because we thought it must be informative for pharmaceutical care especially in patients with diabetes mellitus. As a result, we measured blood glucose levels in all patients and could detect an abnormal increase in the blood glucose levels in some patients. In this study, we assessed the frequency of elevation in the blood glucose levels during chemotherapy for patients with colorectal cancer. An abnormal increase in the blood glucose levels over 200 mg/dl was observed in 8 of the 30 patients in the DEX+ group. Three of these patients were diagnosed with diabetes mellitus during chemotherapy.
These patients were immediately administered oral anti-diabetic drugs after the diagnosis, and the chemotherapy was continued.
In our present study, since the chemotherapeutic drugs and prophylactic DEX, as an antiemetic, were co-administered, we could not determine whether the elevation in the blood glucose level was caused by DEX alone. However, since steroids increase the blood glucose levels 1, 5) , it is likely that the elevation in the blood glucose levels in the 8 patients reported in our study was caused by DEX treatment. In Table 2 and Fig. 3 , we observed no clear correlation between the elevation of blood glucose levels and the cumulative amount of DEX dose, which is consistent with the observations from our previous report 5) . This implies that routine monitoring and early detection of abnormal elevations in the blood glucose levels are essential. Moreover, as a tool to diagnose diabetes, the HbA1c levels might provide a better index for monitoring the side effects of chemotherapy regimens with DEX treatment. Although HbA1c level is a useful index for the long-term monitoring of diabetes mellitus, careful monitoring of the blood glucose level is important for early detection of diabetes mellitus. In our retrospective study, the data on the HbA1c levels were not available for all patients. None of the combined medicines for the BS+ patients listed in Table 2 reported an increase in the blood glucose levels.
Adequate glycemic control is essential for the effective completion of chemotherapeutic regimens. Elevated blood glucose levels have not yet been evaluated as a side effect of typical chemotherapy regimens for colorectal cancer 10) . The results of our study suggest that elevated blood glucose levels can be associated with the administration of DEX during certain chemotherapeutic regimens for colorectal cancer. Moreover, type 2 diabetes has been reported to increase the risk for colorectal cancer 13) . Furthermore, patients with increased insulin and glucose levels are known to be at a higher risk for adenoma recurrence, and this risk is even greater in patients with elevated blood glucose levels 14, 15) . Increased insulin levels can also decrease the efficacy of anti-cancer drugs, e.g., an in vitro report suggested that elevated insulin levels increase the resistance of cancer cell lines to chemotherapeutic drugs 16) .
Currently, a significant amount of epidemiologic evidence suggests that metabolic syndrome can increase the risk for colorectal cancer, and that hyperinsulinemia may play a pivotal role in increasing this risk, although the precise mechanism underlying the contribution of these factors to the pathogenesis of colorectal cancer is unknown.
On the basis of the results of our present study and those of the previous studies, we conclude that appropriate pharmaceutical care with routine monitoring and early detection of abnormal elevation in the blood glucose levels is necessary for the effectively completing chemotherapy and preventing diabetes during DEX treatment. Cancer chemotherapy may cause serious adverse effects, and its frequency and severity vary among patients. Therefore, it is important to prevent or manage the side effects in individual patients with careful support not only from medical doctors but also from professionals such as nurses and pharmacists. As shown in Fig. 3 , precise control of blood glucose levels is not easily achievable. However, supportive care of patients with appropriate communication in combination with careful monitoring of the blood glucose levels and other laboratory parameters is necessary, and may contribute to an improvement in the QOL of cancer patients.
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